The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Merck; Sanofi
Research Funding - Janssen Oncology
Travel, Accommodations, Expenses - Genentech/Roche
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
 
Karim Fizazi
Honoraria - Amgen; Astellas Pharma; Janssen; Merck; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
David R. Shaffer
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - Exelixis; Genentech/Roche
Speakers' Bureau - Exelixis
 
Russell Pachynski
No Relationships to Disclose
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Marika Ciprotti
No Relationships to Disclose
 
George Kong
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Charles J. Ryan
Honoraria - Astellas Pharma; Bayer; Janssen Oncology
Consulting or Advisory Role - Bayer; Ferring; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi